Zoledronic acid: a once‐yearly injection for osteoporosis
نویسندگان
چکیده
منابع مشابه
ZOMETA (zoledronic acid) Injection Label
These highlights do not include all the information needed to use ZOMETA safely and effectively. See full prescribing information for ZOMETA. ZOMETA (zoledronic acid) Injection Ready-to-Use Solution for Intravenous Infusion (For Single Use) Concentrate for Intravenous Infusion Initial U.S. Approval: 2001 ----------------------------RECENT MAJOR CHANGES-------------------------Warnings and Preca...
متن کاملYearly zoledronic acid in postmenopausal osteoporosis.
To the Editor: In their report on the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial, Black et al. (May 3 issue)1 conclude that a onceyearly infusion of zoledronic acid reduces the risk of vertebral, hip, and other fractures. Although this is a well-designed and well-done study, we are concerned about the increase in atrial fibrillation i...
متن کاملZoledronic acid infusion for prevention and treatment of osteoporosis
Osteoporotic fractures are associated with significant morbidity, reduced quality of life, increased mortality, and high health care costs. Bisphosphonates are standard therapy for treatment of osteoporosis. However, patient compliance and persistence with oral weekly or monthly bisphosphonate therapy are suboptimal and may lead to reduced effectiveness. Zoledronic acid (ZOL) is an intravenous ...
متن کاملSix monthly intravenous zoledronic acid in childhood osteoporosis
Childhood osteoporosis can be treated with intravenous bisphosphonates in order to improve bone mass and density. The aims of this study were to evaluatethe safety and efficacy of six-monthly zoledronic acid (ZA) in children with osteoporosis. A retrospective cohort study of 27 patients (16 males and 11 females) weretreated with six-monthly ZA (0.05mg/kg/dose) for a minimum of one year.17 patie...
متن کاملFracture risk and zoledronic acid therapy in men with osteoporosis.
BACKGROUND Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Prescriber
سال: 2008
ISSN: 0959-6682,1931-2253
DOI: 10.1002/psb.254